Bellevue Group AG Raises Stock Holdings in Glaukos Co. (NYSE:GKOS)

Bellevue Group AG grew its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 12.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 62,983 shares of the medical instruments supplier's stock after acquiring an additional 7,057 shares during the period. Bellevue Group AG owned 0.11% of Glaukos worth $8,205,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GKOS. Point72 Asset Management L.P. bought a new position in shares of Glaukos during the second quarter worth approximately $67,460,000. Primecap Management Co. CA grew its position in Glaukos by 43.9% during the second quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier's stock worth $144,483,000 after buying an additional 372,180 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Glaukos by 148.3% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier's stock worth $48,805,000 after acquiring an additional 246,322 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Glaukos by 47.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier's stock valued at $83,609,000 after acquiring an additional 207,338 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its position in shares of Glaukos by 24.0% during the 2nd quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier's stock valued at $95,112,000 after acquiring an additional 155,653 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently commented on GKOS. Stifel Nicolaus raised their price target on Glaukos from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. StockNews.com raised shares of Glaukos from a "sell" rating to a "hold" rating in a report on Monday, October 21st. JPMorgan Chase & Co. boosted their target price on shares of Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. BTIG Research increased their price target on shares of Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Finally, Piper Sandler set a $140.00 price objective on shares of Glaukos in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $135.45.

Glaukos Price Performance

Shares of NYSE GKOS traded up $0.96 during mid-day trading on Friday, hitting $143.65. 165,871 shares of the stock traded hands, compared to its average volume of 570,025. The company has a market cap of $7.92 billion, a PE ratio of -47.57 and a beta of 1.02. Glaukos Co. has a twelve month low of $59.58 and a twelve month high of $146.86. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The firm has a 50 day simple moving average of $134.13 and a two-hundred day simple moving average of $124.86.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. During the same period last year, the firm posted ($0.50) earnings per share. The business's revenue for the quarter was up 23.9% on a year-over-year basis. As a group, equities research analysts forecast that Glaukos Co. will post -1.91 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In related news, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares of the company's stock, valued at $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. This trade represents a 8.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.